

Sepsis Update Advisory Committee Interests Register

Register last updated: 22 February 2025

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|-----------------|-------------------------------|--|---|----------------|-------------------|-----------------|--|
| Ann Hoskins | Chair | Direct non-financial professional and personal interests | Advocate / member of the British Association of Child and Adolescent PH. | | Dec-2021 | Ongoing | Declare and participate. Rationale: Not specific to the update of the guideline |
| Ann Hoskins | Chair | Direct non-financial professional and personal interests | Board Member, Plus Dane Housing Association | 2016 | May 2022 | Ongoing | Declare and participate. Rationale: Not specific to the update of the guideline |
| Ann Hoskins | Chair | Direct financial | Independent Public Health Consultant | | | Ongoing | Declare and participate Rationale: Self-employed providing NHS services. |
| Samina Begum | Lay member | Nil | Nil | Nil | Nil | Nil | Nil |
| Louise Bradbury | Consultant Nurse for Outreach | Direct financial | Critical Care Outreach and Deteriorating Patient Lead, Watford General Teaching Hospital | Jan-21 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Tumena Corrah | Consultant in Acute Medicine | Non-financial professional and personal | Arberry J, Henry Z, Corrah T. A simple measure to improve sepsis documentation and coding. Clin Med (Lond) 2021; 21(3):222-225. | 2021 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|---------------|----------------------------------|---|--|--------|--------|---------|--|
| Tumena Corrah | Consultant in Acute Medicine | Non-financial professional and personal | Enoch DA, Cargill JS, Laing R, Herbert S, Corrah TW , Brown NM. Value of CT-guided biopsy in the diagnosis of septic discitis. J Clin Pathol 2008; 61(6):750-753. | Jun-08 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline No action needed other than process of open declaration. |
| Tumena Corrah | Consultant in Acute Medicine | Direct financial | Consultant in infectious Diseases and Acute Medicine and Honorary Senior Clinical Lecturer (Imperial College London) | Apr-15 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment at educational institution. |
| Peter Gosling | Lay Member | Nil | Nil | Nil | Nil | Nil | Nil |
| Alasdair Gray | Consultant in Emergency Medicine | Non-financial professional and personal | Co-Chief Investigator. Feasibility of 5% Albumin compared with Balanced crystalloid, intravenous fluid resuscitation in adult Sepsis patients presenting as an emergency to hospital: The ABC Sepsis Trial. Finished recruitment, in follow up. Feasibility trial | 2020 | May-22 | Ongoing | Partial exclusion Rationale: Member was not allowed to participate in the drafting of recommendations on IV fluids. |
| Alasdair Gray | Consultant in Emergency Medicine | Non-financial professional and personal | Co-investigator. Vasopressors in Sepsis (EVIS). NIHR HTA programme (NIHR132594); (2021-2026). Pragmatic trial of low dose early vasopressor compared with current standard of care | 2021 | May-22 | Ongoing | Partial exclusion Rationale: Member was not allowed to participate in the drafting of recommendations on vasopressors.. |

| | | | | | | | |
|---------------|----------------------------------|----------------------|---|------------|-------------|---------|---|
| | | | in patients with sepsis presenting to UK EDs. Trial currently in set up. | | | | |
| Alasdair Gray | Consultant in Emergency Medicine | Direct financial | Consultant in Emergency Medicine, NHS Lothian and Honorary Professor, University of Edinburgh | 2021 | May-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Alasdair Gray | Consultant in Emergency Medicine | Indirect financial | Co-applicant on an NIHR platform trial on biomarkers and prognosis for patients presenting to emergency care with presumed infection. | | December-23 | | Declare and participate Rationale: An independent committee will be deciding which biomarkers will go into the trial. Member will provide updates for us as this develops so we can check for conflicts |
| Alasdair Gray | Consultant in Emergency Medicine | Direct financial | Consultancy work for MeMed for their infection biomarker. Fee for this work is to be paid to NHS Lothian. | January-24 | Dec-23 | Ongoing | Declare and participate Rationale: Not-specific. To be reviewed once searches are completed as this does connect to the scope. Updated with additional information from the member. The work conducted with MeMed was on a combination of three biomarkers. IP-10, CRP and TRAIL. These are connected to pneumonia no sepsis no not specific to the scope of this guideline. |
| Alasdair Gray | Consultant in Emergency Medicine | Direct non-financial | Author on Albumin Versus Balanced Crystalloid for the Early Resuscitation of | Jun-24 | Aug-24 | | Partial exclusion Rationale: Member was not allowed to participate in the |

| | | | | | | | |
|----------------|--------------------------------------|---|--|--------------|--------------|---------|--|
| | | professional and personal | Sepsis: An Open Parallel-Group Randomized Feasibility Trial. The ABC-Sepsis Trial | | | | drafting of recommendations on IV fluids. |
| Jeremy Henning | Consultant in Critical Care Medicine | Direct financial | Consultant Intensive Care Medicine, South Tees NHS Foundation Trust | April-02 | May-22 | Ongoing | Declare and participate Rationale: salaried employment in the NHS. |
| Jeremy Henning | Consultant in Critical Care Medicine | Non-financial professional and personal | Local Principle Investigator for SEPTIC at James Cook University Hospital. Restricting early fluids in sepsis and PCR testing | February -24 | February -24 | | Declare and Participate Rationale: Open declaration is sufficient mitigation. We are not including this study in our review and there is no personal financial benefit. |
| Tessa Lewis | General Practitioner | Non-financial professional and personal | Developed webinar & slide set on decision points for remote management of common infections. Topics included otitis media, sinusitis, cough and other common infections - Included within paid role as medical adviser to PHE primary care intervention unit/ TARGET toolkit | Dec-21 | Oct-21 | 2022 | Declare and participate Rationale: Not specific to the scope of the guideline |
| Tessa Lewis | General Practitioner | Non-financial professional and personal | Chair of the NICE Pneumonia update committee | Jul-22 | Sep-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Tessa Lewis | General Practitioner | Direct financial | General practitioner (locum) with special interest in frailty | Aug-21 | May-22 | Ongoing | Declare and participate |

| | | | | | | | |
|----------------|------------------------|---|--|--------|--------|---------|--|
| | | | | | | | Rationale: Salaried employment in the NHS. |
| Tessa Lewis | General Practitioner | Non-financial professional and personal | Royal College of General Practitioners representative on UKHSA ESPAUR | Oct-22 | Apr-23 | Ongoing | Declare and participate. Rationale: A survey of anti-microbial resistance but not specific to sepsis. |
| Tessa Lewis | General Practitioner | Non-financial professional and personal | Royal College of General Practitioners representative on UK Standards for Microbiology Investigations steering committee. | Apr-23 | Apr-23 | Ongoing | Declare and participate. Rationale: Not specifically looking at Sepsis so not specific to the scope of the guideline. |
| Tessa Lewis | General Practitioner | Direct financial | Participated in a BMJ masterclass webinar: "Antimicrobial stewardship from the frontline – updates and opportunities". Honorarium paid via BMJ from <i>Fondazione Menarini</i> . | Nov-24 | Dec-24 | Nov-24 | Declare and participate. Rationale: Anti-microbial stewardship is not a sepsis-specific topic and the talk whilst sponsored by the Menarini group was not about any specific pharmaceuticals. |
| Paddy McMaster | Co-Opted Paediatrician | Non-financial professional and personal | Member of the NICE Pneumonia Committee | Oct-23 | May-24 | Ongoing | Declare and participate Rationale: Membership on other NICE committees is not a conflict. |
| Paddy McMaster | Co-Opted Paediatrician | Non-financial professional and personal | On steering committee of UK Paediatric Antimicrobial Stewardship – lead for Antimicrobial Paediatric Guide | 2019 | May-24 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|--------------------|------------------------|---|---|--------|--------|---------|--|
| Paddy McMaster | Co-Opted Paediatrician | Direct Financial | Consultant in Paediatric Infectious Diseases at North Manchester General Hospital and Royal Manchester Children's Hospital | 2011 | May-24 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS |
| Paddy McMaster | Co-Opted Paediatrician | Non-financial professional and personal | BATCH study procalcitonin in suspected infection in children Biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: statistical analysis plan for the BATCH trial and PRECISE sub-study - PubMed (nih.gov) | 2019 | May-24 | Ongoing | Declare and participate Rationale: Not in scope. The BATCH trial looked at procalcitonin in childhood sepsis. |
| Barry Murphy-Jones | Paramedic | Non-financial professional and personal | Murphy-Jones, B. & Shaw, J. (2016). Level of Sepsis Knowledge In UK Ambulance Services. <i>Emergency Medical Journal</i> , 33: e10-e11. | 2016 | May-22 | Nil | Declare and participate Rationale: Not specific to the scope of the guideline |
| Barry Murphy-Jones | Paramedic | Direct financial | Senior Lecturer – Paramedic Science, University of Hertfordshire | Jan-22 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in higher education. |
| Barry Murphy-Jones | Paramedic | Direct financial | Associate Lecturer, Angela Ruskin University | Nov-19 | Oct-22 | May-24 | Declare and participate |

| | | | | | | | |
|--------------------|--------------------------------------|---|---|---------|---------|---------|--|
| | | | | | | | Rationale: Salaried employment in higher education. |
| Barry Murphy-Jones | Paramedic | Direct financial | Advanced Paramedic Practitioner – Critical Care, London Ambulance Service | Sep-17 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Barry Murphy-Jones | Paramedic | Non-financial professional and personal | ERC young Masterclass – potential peer reviewer for Resuscitation Plus | Sept-23 | Sept-23 | July-24 | Declare and participate Not specific to the scope of the guideline |
| Barry Murphy-Jones | Paramedic | Non-financial professional and personal | Reviewer of the Association of Ambulance Chief Executives (AACE) Sepsis guidelines, incorporating NICE recommendations and other current evidence related to pre-hospital care. AACE produce the Ambulance JRCALC guidelines | Jun-24 | Jun-24 | Ongoing | Declare and participate Rationale: This is not in conflict with our recommendations and will not influence his role on the committee. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Direct financial | Speaker honoraria from Fresenius Medical Care, Baxter and Biomerieux – “ <i>Acute kidney injury in critically ill patients</i> ”. (payment was used to support research studies) | Jan-20 | May-22 | Mar-22 | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Indirect financial | Research funding from Fresenius Medical Care, Baxter, Biomerieux and LaJolla Pharma (funding was paid to Guy’s & St Thomas) | Jan-19 | May-22 | Feb-22 | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|-------------------|--------------------------------------|---|--|-----------|--------|-----------|--|
| | | | Hospital London and was used for 2 research studies exploring the epidemiology of acute kidney injury in critically ill patients in the Intensive Care Unit) | | | | |
| Marlies Ostermann | Consultant in Critical Care Medicine | Direct financial | Member of advisory committee for Mission Therapeutics and Pfizer | Jan-21 | May-22 | Feb-22 | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Deputy Co-Chair of Surviving Sepsis Guidelines Committee | 2019 | May-22 | 2021 | Declare and participate Rationale: Historic Chairing that concluded before Marlies Joined this committee. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Member of Surviving Sepsis Research Committee | July 2021 | May-22 | Ongoing | Declare and participate Rationale: Open declaration is sufficient mitigation. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Principal investigator of REVIVAL trial (RCT comparing the role of recombinant alkaline phosphatase in critically ill patients with sepsis and acute kidney injury) | 2021 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Principal Investigator of CLASSIC trial (RCT comparing restrictive versus liberal fluid management in patients with septic shock) - Meyhoff TS, Hjortrup PB, Wetterslev J et al. Restriction of Intravenous Fluid in ICU | 2020 | May-22 | June 2022 | Declare and participate Rationale: Interest is in scope for the guideline update, and the study was identified during searches, it did not meet the |

| | | | | | | | |
|-------------------|---|---|--|------|--------|-----------------|--|
| | | | Patients with Septic Shock.. N Engl J Med. 2022 Jun 30;386(26):2459-2470. doi: 10.1056/NEJMoA2202707 | | | | criteria for inclusion in the review. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Principal investigator of ATHOS III trial (RCT investigating the role of Angiotensin II in vasodilatory shock) - Khanna A, English SW, Wang XS et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoA1704154 | 2015 | May-22 | 2017 | Declare and participate Rationale: Interest is not specific to the scope of this update and open declaration is sufficient mitigation. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Director of Research, Chair of Standards Committee and Council member of Intensive Care Society UK | 2020 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Chair of Research Committee of European Society of Intensive Care Medicine and Member of Executive Committee | 2021 | May-22 | October 2023 | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Member of AKINow Committee of the American Society of Nephrology | 2020 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|-------------------|--------------------------------------|---|--|------|--------|---------|---|
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Coordinator of European Sepsis Survey | 2020 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Member of Royal Society of Medicine Critical Care Council | 2020 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Spoden M et al. Occurrence and risk factors for new dependency on chronic care, respiratory support, dialysis and mortality in the first year after sepsis. | 2022 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Bakker J et al. Current practice and evolving concepts in septic shock resuscitation. Intensive Care Med 2021;48:148-163 | 2021 | May-22 | | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Evans L et al. Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021. Crit Care Med 2021;49(11):197-1982 | 2021 | May-22 | | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Evans L et al. Surviving sepsis campaign: international guidelines for the management of sepsis and septic shock. Intensive | 2021 | May-22 | | Declare and participate |

| | | | | | | | |
|-------------------|--------------------------------------|---|---|--------|--------|---------|---|
| | | | Care Med 2021;47(11):1181-1247 | | | | Rationale: Interest is specific and open declaration is sufficient mitigation. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | De Backer D et al. Challenges in the management of septic shock: a narrative review. Intensive Care Med 2019;Feb 11 | 2019 | May-22 | | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Direct financial | Consultant in Critical Care & Nephrology, Guy's and St. Thomas Hospital | Nov-05 | May-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Honorary Senior Lecturer, King's College London | Dec-09 | May-22 | Sept 21 | Declare and participate Rationale: Non-salaried employment.in educational services. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Direct financial | Professor in Intensive Care Medicine, King's College London | Sep-21 | May-22 | Ongoing | Declare and participate Rationale: Salaried employment in educational services. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Direct financial | Member of advisory meeting for Alexion | Apr-22 | May-22 | | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. |
| Ashley Reed | Emergency Consultant | Direct financial | Consultant Practitioner (Paramedic), Southend | Feb-23 | Apr-24 | Ongoing | Declare and participate |

| | | | | | | | |
|-------------|----------------------|---|--|--------|--------|---------|---|
| | | | University Hospital NHS Foundation Trust | | | | Rationale: Salaried employment in the NHS. |
| Ashley Reed | Emergency Consultant | Direct financial | Visiting lecturer at the University of Hertfordshire – teaching on paramedic science BSc and MSc modules | Sep-21 | May-24 | Ongoing | Declare and participate Rationale: Salaried employment in higher education |
| Ashley Reed | Emergency Consultant | Non-financial professional and personal | Principal Investigator in an NIHR Study – Opt-out testing for HIV, Hep B and Hep C in the Emergency Department for Southend ED site. | Apr-24 | Apr-24 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Ashley Reed | Emergency Consultant | Non-financial professional and personal | Prepared case report for publication of: “Recurrent skin and soft tissue infections (SSTIs) in three family members caused by meticillin resistant staphylococcus aureus (MRSA) with panton-valentine leukocidin (PVL) endotoxin.” | Apr-24 | Apr-24 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Ashley Reed | Emergency Consultant | Non-financial professional and personal | Principal Investigator on research study – DrUBER: Drone Network for Medical Emergency Delivery. | Sep-24 | Sep-24 | | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Ashley Reed | Emergency Consultant | Non-financial professional and personal | Professional Doctorate student with Salford University | Sep-24 | Sep-24 | | Declare and participate Rationale: Not specific to the scope of the guideline update |

| | | | | | | | |
|----------------|---|------------------|--|----------|---------|---------|--|
| Giovanni Satta | Consultant Microbiologist/Infectious Disease Specialist | Direct financial | Consultant in Infection (Microbiology and Infectious Diseases) and Infection Control Doctor, University College London Hospitals | Feb-21 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment at educational institution. |
| Giovanni Satta | Consultant Microbiologist/Infectious Disease Specialist | Direct financial | Associate Professor, University College London Hospitals | Feb-21 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in educational services. |
| Mervyn Singer | Topic Adviser | Direct financial | Professor of Intensive Care Medicine and Director, Centre for Intensive Care Medicine, Division of Medicine, University College London | Oct-2001 | June-23 | Ongoing | Declare and participate Rationale: Salaried employment at educational institution. |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, Enlivex - Israeli company developing a novel cell-based therapy for sepsis | Dec-19 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, deepUII – Spanish company developing a molecular diagnostic for pathogens (transcriptomic technology) which they are planning to combine with a Raman spectroscopic approach for rapid assessment of antibiotic susceptibility. | Apr-21 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update. |

| | | | | | | | |
|---------------|---------------|------------------|---|---------|---------|---------|--|
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, Safeguard Biosystems – US company developing a molecular diagnostic for pathogens (transcriptomic technology) | Dec-21 | June-23 | Ongoing | Complete Exclusion Rationale: This is specific to the recommendations being updated in review questions 1 and 2, so the individual sat out of the discussion and recommendation making for these reviews. |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, Aptarion - Swiss company developing a novel drug for sepsis | May-22 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, Roche Diagnostics – multinational company developing novel pathogen diagnostics | Nov-22 | June-23 | Feb-23 | Complete Exclusion Rationale: This is specific to the recommendations being updated in review questions 1 and 2, so the individual sat out of the discussion and recommendation making for these reviews |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, Matisse Pharmaceuticals – Dutch company developing a novel drug for sepsis - A modified heparin that binds histones released from neutrophils in sepsis. | Sept-23 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |

| | | | | | | | |
|---------------|---------------|---|---|------|---------|----------|---|
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Council member (and past-Chair) International Sepsis Forum – group of sepsis experts who organise a yearly international sepsis meeting, colloquia, and provide advice to Industry | 2009 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Member, Acute Deterioration Board, NHS England | 2021 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Vice-Chair, Academy of Medical Royal Colleges Working Group on initial antibiotic treatment for sepsis | 2019 | June-23 | 2023 | Declare and participate Rationale: Historic chairing that ended as the individual joined this committee in June 2023 |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Trustee for the University College London Hospitals NHS Foundation Trust (UCLH) Charity. The role involved giving input into how money was invested and spent (applications for internal hospital grants, quality improvement projects, patient experience enhancements etc.) | 2017 | June-23 | March-23 | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | UCL Technology Fund Award to develop novel in-house therapy for sepsis | 2021 | June-23 | 2023 | Declare and participate Rationale: Not specific to the scope of the guideline update |

| | | | | | | | |
|---------------|---------------|---|---|------|---------|---------|--|
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Principal clinical investigator (in conjunction with Oxford Optronix) - Wellcome Trust/Dept Health Award to develop novel monitor for monitoring organ perfusion adequacy | 2016 | June-23 | 2023 | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Pre-symptom Health – unpaid advisor to Ministry of Defence (DSTL) spin-off company developing novel sepsis diagnostic test | 2019 | June-23 | Ongoing | Complete exclusion Rationale: This is specific to the recommendations being updated in review questions 1 and 2, so the individual sat out of the discussion and recommendation making for these reviews |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Clinical studies performed on the UCLH intensive care unit on novel sepsis and pathogen diagnostics - Gentian, Biomerieux | 2019 | June-23 | Ongoing | Complete Exclusion Rationale: This is specific to the recommendations being updated in review questions 1 and 2, so the individual sat out of the discussion and recommendation making for these reviews. |
| Mervyn Singer | Topic Adviser | Direct financial | Rosetrees Trust Award – preclinical studies to enhance activity of existing antibiotics by incorporation into cationic liposomes and addition of DNA nanotubes | 2021 | June-23 | 2023 | Declare and participate Rationale: Not specific to the scope of the guideline update |

| | | | | | | | |
|---------------|---------------|--------------------|---|---------|---------|---------|---|
| Mervyn Singer | Topic Adviser | Indirect financial | Deltex Medical – UK company making haemodynamic monitoring device- royalties and advisory board honorarium paid into my Research Fund held by UCLH Charity. I have sole control over these funds along with an intensive care colleague. | 2000 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | Biotest – German company producing immunoglobulin therapy for sepsis - advisory board - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague. | 2016 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | Biomerieux – French company developing novel pathogen diagnostics - advisory board and educational videos - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague. | 2019 | June-23 | Ongoing | Complete Exclusion Rationale: This is specific to the recommendations being updated in review questions 1 and 2, so the individual sat out of the discussion and recommendation making for these reviews |
| Mervyn Singer | Topic Adviser | Indirect financial | Fresenius - German company producing intravenous fluids – chair of satellite meeting, speaker at educational meeting - honorarium paid into my | June-23 | June-23 | Oct-23 | Declare and participate Rationale: Not specific to the scope of the guideline update as it was about fluids relating |

| | | | | | | | |
|---------------|---------------|--------------------|--|---------|---------|---------|---|
| | | | Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague. | | | | to renal replacement as opposed to IV. |
| Mervyn Singer | Topic Adviser | Indirect financial | Hemotune – Swiss company developing extracorporeal therapy for sepsis - advisory board - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague. | Sept-21 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | NewB - Hong Kong-based company developing new therapy for ischaemia-reperfusion injury - chair of DSMC honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague. | Oct-18 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | Pfizer – multinational company and manufacturer of novel antibiotic - speaking at satellite meeting - honorarium paid into my Research Fund held by UCLH Charity. I have sole control over these funds along with an intensive care colleague. | Mar-23 | June-23 | Mar-23 | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | Pfizer - multinational company and manufacturer | Nov-22 | June-23 | Nov-22 | Declare and participate |

| | | | | | | | |
|---------------|---------------|--------------------|--|--------|--------|--|---|
| | | | of novel antibiotic - advisory Board - honorarium paid into my Research Fund held by UCLH Charity. I have sole control over these funds along with an intensive care colleague. | | | | Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | ProMISe (funded by NIHR HTA Programme) Co-funding applicant and contributor - Protocolized Management in Sepsis (ProMISe): A multi-centre, randomized controlled trial of the clinical and cost-effectiveness of early goal-directed protocolized resuscitation for emerging septic shock. https://pubmed.ncbi.nlm.nih.gov/26597979/ | Nov-19 | Dec-23 | | Declare and participate Rationale: This review was not included in our evidence reports. |
| Mervyn Singer | Topic Adviser | Indirect financial | NIHR Efficacy and Mechanism Evaluation Programme Award 15/99/02 Co-funding applicant and contributor - Biomarker-guided Duration of Antibiotic treatment in hospitalised Patients with moderate to severe Sepsis. The ADAPT-Sepsis Trial. | Apr-23 | Dec-23 | | Declare and participate Rationale: This review was not included in our evidence reports. |

| | | | | | | | |
|---------------|---------------|--------------------|---|--------|--------|---------|---|
| | | | https://journals.sagepub.com/doi/full/10.1177/17511437231169193 | | | | |
| Mervyn Singer | Topic Adviser | Indirect financial | NIHR Efficacy and Mechanism Evaluation Programme Award Co-funding applicant and contributor - Study into the Reversal of Septic Shock with Landiolol (STRESS-L) https://pubmed.ncbi.nlm.nih.gov/33593781/ | Feb-21 | Dec-23 | | Declare and participate Rationale: This review was not included in our evidence reports. |
| Mervyn Singer | Topic Adviser | Indirect financial | NIHR Research Award 17/136/02 Co-funding applicant and contributor - Sepsis Trials in Critical Care (SepTIC) https://fundingawards.nihr.ac.uk/award/17/136/02 | May-22 | Dec-23 | Ongoing | Declare and participate Rationale: This review was not included in our evidence reports. |
| Mervyn Singer | Topic Adviser | Indirect financial | EU DLV-676129 Marie Curie Innovative Training Network Award [€546,576] European Sepsis Academy: towards new biomarkers to improve sepsis management (Principal Investigator at UCL) | Mar-16 | Dec-23 | Feb-20 | Declare and participate Rationale: This review was not included in our evidence reports. |
| Mervyn Singer | Topic Adviser | Indirect financial | Innovate UK Biomedical Catalyst Early Stage Award | 2017 | Dec-23 | 2019 | Declare and participate |

| | | | | | | | |
|---------------|---------------|--------------------|---|--------|--------|---------|---|
| | | | to Mologic Ltd 82371-510474 [£1,255,191] Principal Clinical Investigator Sepsis Alert Test | | | | Rationale: This review was not included in our evidence reports. |
| Mervyn Singer | Topic Adviser | Indirect financial | MRC Research Award (MR/T025441/1) [£841,264] Reeder JB, Singer M. Co- funding applicant and contributor - Optimisation of the manufacture of a homogeneous synthetic hemoglobin as a novel Oxygen Therapeutic / Blood Substitute | Nov-20 | Dec-23 | Jul-23 | Declare and participate Rationale: This review was not included in our evidence reports. |
| Mervyn Singer | Topic Adviser | Indirect financial | UCL Technology Fund Award (UTF-21-006) [£150,000] Singer M, Kleyman A, Press A, Bauer M. Principal funding applicant - Development of a phytosterol therapy for sepsis-induced myocardial depression | 2022 | Dec-23 | 2023 | Declare and participate Rationale: This review was not included in our evidence reports. |
| Mervyn Singer | Topic Adviser | Direct financial | Will sit on an advisory board for Sanofi as they develop a new vaccine to prevent urosepsis. Honorarium to be paid. | Oct-24 | Nov-24 | Ongoing | Declare and participate Rationale: Sanofi are not currently manufacturing any pharmaceuticals in scope. |
| Mervyn Singer | Topic Adviser | Direct financial | Will sit on an advisory board for Bayer as they develop a new sepsis drug. Information to follow after contract arrangements. Honorarium | Jan-25 | Nov-24 | Ongoing | Declare and participate Rationale: Bayer are not currently manufacturing any pharmaceuticals in scope, but |

| | | | | | | | |
|---|--|---|--|--------|--------|---------|--|
| | | | will be paid to his into his research fund. | | | | we will observe this declaration and reevaluate once more information is available on the drug in development. |
| Kirstie Tomlinson | Mental Health Professional (co-opted) | Non-financial professional and personal | Advanced Clinical Practitioner Mental Health Services for Older People, Nottinghamshire Healthcare NHS Foundation Trust. | 2022 | Apr-24 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| | | | | | | | |
| | | | | | | | |
| Savio Fernandes (resigned from the committee January 2024) | Consultant Haemoncologist | Direct financial | Consultant in Haematology, Didley Group NHS Foundation Trust | | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Erum Khan (resigned from the committee September 2024) | Consultant Obstetrician | Non-financial professional and personal | RCOG Patient Safety Committee member | May-22 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Erum Khan (resigned from the committee September 2024) | Consultant Obstetrician | Direct financial | Consultant Obstetrician and Gynaecologist, Milton Keynes University Hospital | Apr-15 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Sally Wood (resigned from the committee June 2024) | Consultant Nurse in Emergency Medicine | Indirect financial | Successful grant from Pfizer to appoint a colleague in a secondment role at NUH for 12months leading on blood culture improvement project. | Oct-21 | May-22 | Apr-23 | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|---|---|---|---|--------|--------|--|--|
| Sally Wood (resigned from the committee June 2024) | Consultant Nurse in Emergency Medicine | Non-financial professional and personal | "Predicting 30-day mortality in patients with sepsis; an exploratory analysis of process or care and patient characteristics" (2018) <i>The journal of Intensive Care Society</i> . Sanderson, M., Moppett, I., Chikhani, M., Simmonds, M., Wood, S., McKeever, T. | 2018 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline |
| Sally Wood (resigned from the committee June 2024) | Consultant Nurse in Emergency Medicine | Non-financial professional and personal | "Improving outcome of sepsis on the ward: introducing the sepsis six bundle" Burke, J., Wood, S., Hermon, A., Szakmany, T., Jan 2019 <i>Nursing in Critical Care BACCN</i> . 24 (1) | Jan-19 | May-22 | | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. Interest will be kept under review depending on the matter under consideration. |
| Sally Wood (resigned from the committee June 2024) | Consultant Nurse in Emergency Medicine | Non-financial professional and personal | "Surviving sepsis beyond intensive care: survival rates at one decade." Dec 2018. Patel, R., Wood, S.D., Ford, A., Hutchinson, A., Weston, V., Simmonds, M., Chikhani, M. <i>Intensive care State of the art 2018 Conference</i> | Dec-18 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline |
| Sally Wood (resigned from the committee June 2024) | Consultant Nurse in Emergency Medicine | Non-financial professional and personal | "Sepsis Bags: Simple method to increase procedure compliance with sepsis six on the ward" (2013) Burke, J., Smith, L., <u>Wood, S.</u> , Hermon, A., Szakmany, T. <i>Poster presentation at ESICM Annual Congress, Paris: LIVES 2013.</i> | 2013 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|---|---|---|--|--------|--------|---------|--|
| Sally Wood (resigned from the committee June 2024) | Consultant Nurse in Emergency Medicine | Direct financial | Recognise and Rescue and Sepsis Matron, Nottingham University Hospitals NHS Trust | 2019 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Sally Wood (resigned from the committee June 2024) | Consultant Nurse in Emergency Medicine | Non-financial professional and personal | Member of the UK Sepsis Practitioner Forum | Oct-22 | Oct-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline. |
| | | | | | | | |

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.